ADTX
Addentax Group Corp. enters into a private placement agreement.
The company agreed to sell shares of its Common Stock to an investor at a price of $4.80 per share in a private placement transaction.
ADTX news
Latest 5 stories · newest Sep 14, 2026
ADTX
Aditxt Amends Note Purchase Agreement to Add Cavalry Fund as New Buyer
Aditxt, Inc. and Ignite Proteomics plan to amend their note purchase agreement to include Cavalry Fund I SPV I LP and issue Additional Notes. This update modifies the financing structure to accommodate the new investor's participation.
ADTX
Nasdaq to suspend Aditxt trading pending final SPAC merger vote
Nasdaq upheld the denial of Aditxt's listing request, suspending trading June 25. The move threatens the company's market access ahead of a shareholder vote to finalize a SPAC merger with Ignite Proteomics.
ADTX
Aditxt amends note purchase agreement to increase principal amount
Aditxt Inc. amended its note purchase agreement to authorize an additional $6,638,970.55 in senior secured notes. The legal agreement updates terms applicable to all buyers.
ADTX
Aditxt appoints Jeffrey M. Busch as interim CEO, replacing founder Amro Albanna
Aditxt Inc. named Jeffrey M. Busch, former CEO of NYSE-listed Global Medical REIT, as interim CEO effective May 31, 2026, while founder Amro Albanna resigned from all company positions. Busch will lead the company's commercialization strategy for its Ignite Proteomics precision oncology diagnostics …
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same ADTX feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/ADTX/newsSTART FREE